Chenodeoxycholic Acid
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
- Chenodeoxycholic Acid
- Chenodeoxycholic Acid: From Bile Acid Metabolism to Homozygous Familial Hypercholesterolemia
Chenodeoxycholic Acid: From Bile Acid Metabolism to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Chenodeoxycholic acid (CDCA) is a naturally occurring bile acid; the current evidence pack does not document a confirmed original indication or mechanism of action for this candidate. The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia, but this prediction is currently supported by the model score alone, with 0 clinical trials and only 1 indirectly related publication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in current evidence pack |
| Predicted New Indication | Homozygous Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for chenodeoxycholic acid, and no original indication is recorded in this evidence pack. This limits our ability to assess mechanistic plausibility for the predicted new indication directly from the source data.
The one literature record retrieved for this candidate is a review of cerebrotendinous xanthomatosis (CTX), a rare bile acid synthesis disorder caused by CYP27A1 mutations that impair bile acid production and lead to cholestanol accumulation. While this publication does not directly address homozygous familial hypercholesterolemia, it does establish that disruptions in bile acid/cholesterol synthesis pathways — the biological space in which CDCA operates as an endogenous bile acid — are mechanistically linked to lipid storage and cholesterol-handling disorders. This offers a plausible, but currently unconfirmed, biological rationale for the TxGNN prediction; it should not be treated as direct clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25424010 | 2014 | Review | Orphanet Journal of Rare Diseases | Comprehensive review of cerebrotendinous xanthomatosis (CTX), a bile acid synthesis disorder caused by CYP27A1 mutations resulting in decreased bile acid synthesis and cholestanol accumulation — relevant background on bile acid/cholesterol metabolism pathways, but not a direct study of the predicted indication |
Germany Market Information
Chenodeoxycholic acid currently has no marketing authorizations recorded in the German market (0 authorizations, market status: not marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no documented original indication, no mechanism-of-action data, no clinical trial evidence, and no marketing authorization in Germany for this candidate. The single available publication addresses a related but distinct bile acid disorder rather than the predicted indication itself, so the prediction currently rests on the TxGNN model score alone.
To proceed, the following is needed:
- Confirmed original indication and mechanism of action (DrugBank query)
- TFDA/manufacturer package insert for warnings and contraindications
- Dedicated preclinical or clinical evidence directly linking chenodeoxycholic acid to lipid metabolism disorders such as homozygous familial hypercholesterolemia
- Safety and drug interaction profile before any S1 initial safety assessment can proceed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.